Pharma & Healthcare

Global FcRn Inhibitor Market Research Report 2025

This report aims to provide a comprehensive presentation of the global market for FcRn Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding FcRn Inhibitor.
The FcRn Inhibitor market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global FcRn Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, by Therapeutic Indications and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the FcRn Inhibitor companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Argenx
UCB Pharma
Immunovant
Johnson & Johnson
Viridian Therapeutics
HanAll Biopharma
Segment by Type
Efgartigimod
Rozanolixizumab
Other
Segment by Therapeutic Indications
Immune Thrombocytopenia
CIDP
Pemphigus & Pemphigoid
Others
Segment by Route of Administration
Intravenous
Subcutaneous
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia & New Zealand
Europe
Germany
France
U.K.
Italy
Ireland
Russia
Rest of Europe
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Israel
United Arab Emirates (UAE)
Saudi Arabia
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, by Therapeutic Indications etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of FcRn Inhibitor company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global FcRn Inhibitor Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Efgartigimod
1.2.3 Rozanolixizumab
1.2.4 Other
1.3 Market by Therapeutic Indications
1.3.1 Global FcRn Inhibitor Market Size Growth Rate by Therapeutic Indications: 2020 VS 2024 VS 2031
1.3.2 Immune Thrombocytopenia
1.3.3 CIDP
1.3.4 Pemphigus & Pemphigoid
1.3.5 Others
1.4 Market by Route of Administration
1.4.1 Global FcRn Inhibitor Market Size Growth Rate by Route of Administration: 2020 VS 2024 VS 2031
1.4.2 Intravenous
1.4.3 Subcutaneous
1.5 Market by Application
1.5.1 Global FcRn Inhibitor Market Growth by Application: 2020 VS 2024 VS 2031
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered
2 Global Growth Trends
2.1 Global FcRn Inhibitor Market Perspective (2020-2031)
2.2 Global FcRn Inhibitor Growth Trends by Region
2.2.1 Global FcRn Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 FcRn Inhibitor Historic Market Size by Region (2020-2025)
2.2.3 FcRn Inhibitor Forecasted Market Size by Region (2026-2031)
2.3 FcRn Inhibitor Market Dynamics
2.3.1 FcRn Inhibitor Industry Trends
2.3.2 FcRn Inhibitor Market Drivers
2.3.3 FcRn Inhibitor Market Challenges
2.3.4 FcRn Inhibitor Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top FcRn Inhibitor Players by Revenue
3.1.1 Global Top FcRn Inhibitor Players by Revenue (2020-2025)
3.1.2 Global FcRn Inhibitor Revenue Market Share by Players (2020-2025)
3.2 Global Top FcRn Inhibitor Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by FcRn Inhibitor Revenue
3.4 Global FcRn Inhibitor Market Concentration Ratio
3.4.1 Global FcRn Inhibitor Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by FcRn Inhibitor Revenue in 2024
3.5 Global Key Players of FcRn Inhibitor Head office and Area Served
3.6 Global Key Players of FcRn Inhibitor, Product and Application
3.7 Global Key Players of FcRn Inhibitor, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 FcRn Inhibitor Breakdown Data by Type
4.1 Global FcRn Inhibitor Historic Market Size by Type (2020-2025)
4.2 Global FcRn Inhibitor Forecasted Market Size by Type (2026-2031)
5 FcRn Inhibitor Breakdown Data by Application
5.1 Global FcRn Inhibitor Historic Market Size by Application (2020-2025)
5.2 Global FcRn Inhibitor Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America FcRn Inhibitor Market Size (2020-2031)
6.2 North America FcRn Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America FcRn Inhibitor Market Size by Country (2020-2025)
6.4 North America FcRn Inhibitor Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe FcRn Inhibitor Market Size (2020-2031)
7.2 Europe FcRn Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe FcRn Inhibitor Market Size by Country (2020-2025)
7.4 Europe FcRn Inhibitor Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific FcRn Inhibitor Market Size (2020-2031)
8.2 Asia-Pacific FcRn Inhibitor Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific FcRn Inhibitor Market Size by Region (2020-2025)
8.4 Asia-Pacific FcRn Inhibitor Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America FcRn Inhibitor Market Size (2020-2031)
9.2 Latin America FcRn Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America FcRn Inhibitor Market Size by Country (2020-2025)
9.4 Latin America FcRn Inhibitor Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa FcRn Inhibitor Market Size (2020-2031)
10.2 Middle East & Africa FcRn Inhibitor Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa FcRn Inhibitor Market Size by Country (2020-2025)
10.4 Middle East & Africa FcRn Inhibitor Market Size by Country (2026-2031)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Argenx
11.1.1 Argenx Company Details
11.1.2 Argenx Business Overview
11.1.3 Argenx FcRn Inhibitor Introduction
11.1.4 Argenx Revenue in FcRn Inhibitor Business (2020-2025)
11.1.5 Argenx Recent Development
11.2 UCB Pharma
11.2.1 UCB Pharma Company Details
11.2.2 UCB Pharma Business Overview
11.2.3 UCB Pharma FcRn Inhibitor Introduction
11.2.4 UCB Pharma Revenue in FcRn Inhibitor Business (2020-2025)
11.2.5 UCB Pharma Recent Development
11.3 Immunovant
11.3.1 Immunovant Company Details
11.3.2 Immunovant Business Overview
11.3.3 Immunovant FcRn Inhibitor Introduction
11.3.4 Immunovant Revenue in FcRn Inhibitor Business (2020-2025)
11.3.5 Immunovant Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Details
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson FcRn Inhibitor Introduction
11.4.4 Johnson & Johnson Revenue in FcRn Inhibitor Business (2020-2025)
11.4.5 Johnson & Johnson Recent Development
11.5 Viridian Therapeutics
11.5.1 Viridian Therapeutics Company Details
11.5.2 Viridian Therapeutics Business Overview
11.5.3 Viridian Therapeutics FcRn Inhibitor Introduction
11.5.4 Viridian Therapeutics Revenue in FcRn Inhibitor Business (2020-2025)
11.5.5 Viridian Therapeutics Recent Development
11.6 HanAll Biopharma
11.6.1 HanAll Biopharma Company Details
11.6.2 HanAll Biopharma Business Overview
11.6.3 HanAll Biopharma FcRn Inhibitor Introduction
11.6.4 HanAll Biopharma Revenue in FcRn Inhibitor Business (2020-2025)
11.6.5 HanAll Biopharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global FcRn Inhibitor Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Efgartigimod
Table 3. Key Players of Rozanolixizumab
Table 4. Key Players of Other
Table 5. Global FcRn Inhibitor Market Size Growth Rate by Therapeutic Indications (US$ Million): 2020 VS 2024 VS 2031
Table 6. Key Players of Immune Thrombocytopenia
Table 7. Key Players of CIDP
Table 8. Key Players of Pemphigus & Pemphigoid
Table 9. Key Players of Others
Table 10. Global FcRn Inhibitor Market Size Growth Rate by Route of Administration (US$ Million): 2020 VS 2024 VS 2031
Table 11. Key Players of Intravenous
Table 12. Key Players of Subcutaneous
Table 13. Global FcRn Inhibitor Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global FcRn Inhibitor Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 15. Global FcRn Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 16. Global FcRn Inhibitor Market Share by Region (2020-2025)
Table 17. Global FcRn Inhibitor Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 18. Global FcRn Inhibitor Market Share by Region (2026-2031)
Table 19. FcRn Inhibitor Market Trends
Table 20. FcRn Inhibitor Market Drivers
Table 21. FcRn Inhibitor Market Challenges
Table 22. FcRn Inhibitor Market Restraints
Table 23. Global FcRn Inhibitor Revenue by Players (2020-2025) & (US$ Million)
Table 24. Global FcRn Inhibitor Market Share by Players (2020-2025)
Table 25. Global Top FcRn Inhibitor Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in FcRn Inhibitor as of 2024)
Table 26. Ranking of Global Top FcRn Inhibitor Companies by Revenue (US$ Million) in 2024
Table 27. Global 5 Largest Players Market Share by FcRn Inhibitor Revenue (CR5 and HHI) & (2020-2025)
Table 28. Global Key Players of FcRn Inhibitor, Headquarters and Area Served
Table 29. Global Key Players of FcRn Inhibitor, Product and Application
Table 30. Global Key Players of FcRn Inhibitor, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global FcRn Inhibitor Market Size by Type (2020-2025) & (US$ Million)
Table 33. Global FcRn Inhibitor Revenue Market Share by Type (2020-2025)
Table 34. Global FcRn Inhibitor Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 35. Global FcRn Inhibitor Revenue Market Share by Type (2026-2031)
Table 36. Global FcRn Inhibitor Market Size by Application (2020-2025) & (US$ Million)
Table 37. Global FcRn Inhibitor Revenue Market Share by Application (2020-2025)
Table 38. Global FcRn Inhibitor Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 39. Global FcRn Inhibitor Revenue Market Share by Application (2026-2031)
Table 40. North America FcRn Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 41. North America FcRn Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 42. North America FcRn Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 43. Europe FcRn Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Europe FcRn Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 45. Europe FcRn Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 46. Asia-Pacific FcRn Inhibitor Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 47. Asia-Pacific FcRn Inhibitor Market Size by Region (2020-2025) & (US$ Million)
Table 48. Asia-Pacific FcRn Inhibitor Market Size by Region (2026-2031) & (US$ Million)
Table 49. Latin America FcRn Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 50. Latin America FcRn Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 51. Latin America FcRn Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 52. Middle East & Africa FcRn Inhibitor Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 53. Middle East & Africa FcRn Inhibitor Market Size by Country (2020-2025) & (US$ Million)
Table 54. Middle East & Africa FcRn Inhibitor Market Size by Country (2026-2031) & (US$ Million)
Table 55. Argenx Company Details
Table 56. Argenx Business Overview
Table 57. Argenx FcRn Inhibitor Product
Table 58. Argenx Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 59. Argenx Recent Development
Table 60. UCB Pharma Company Details
Table 61. UCB Pharma Business Overview
Table 62. UCB Pharma FcRn Inhibitor Product
Table 63. UCB Pharma Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 64. UCB Pharma Recent Development
Table 65. Immunovant Company Details
Table 66. Immunovant Business Overview
Table 67. Immunovant FcRn Inhibitor Product
Table 68. Immunovant Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 69. Immunovant Recent Development
Table 70. Johnson & Johnson Company Details
Table 71. Johnson & Johnson Business Overview
Table 72. Johnson & Johnson FcRn Inhibitor Product
Table 73. Johnson & Johnson Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 74. Johnson & Johnson Recent Development
Table 75. Viridian Therapeutics Company Details
Table 76. Viridian Therapeutics Business Overview
Table 77. Viridian Therapeutics FcRn Inhibitor Product
Table 78. Viridian Therapeutics Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 79. Viridian Therapeutics Recent Development
Table 80. HanAll Biopharma Company Details
Table 81. HanAll Biopharma Business Overview
Table 82. HanAll Biopharma FcRn Inhibitor Product
Table 83. HanAll Biopharma Revenue in FcRn Inhibitor Business (2020-2025) & (US$ Million)
Table 84. HanAll Biopharma Recent Development
Table 85. Research Programs/Design for This Report
Table 86. Key Data Information from Secondary Sources
Table 87. Key Data Information from Primary Sources
Table 88. Authors List of This Report


List of Figures
Figure 1. FcRn Inhibitor Picture
Figure 2. Global FcRn Inhibitor Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global FcRn Inhibitor Market Share by Type: 2024 VS 2031
Figure 4. Efgartigimod Features
Figure 5. Rozanolixizumab Features
Figure 6. Other Features
Figure 7. Global FcRn Inhibitor Market Size Comparison by Therapeutic Indications (2020-2031) & (US$ Million)
Figure 8. Immune Thrombocytopenia Features
Figure 9. CIDP Features
Figure 10. Pemphigus & Pemphigoid Features
Figure 11. Others Features
Figure 12. Global FcRn Inhibitor Market Size Comparison by Route of Administration (2020-2031) & (US$ Million)
Figure 13. Intravenous Features
Figure 14. Subcutaneous Features
Figure 15. Global FcRn Inhibitor Market Size by Application (2020-2031) & (US$ Million)
Figure 16. Global FcRn Inhibitor Market Share by Application: 2024 VS 2031
Figure 17. Hospitals Case Studies
Figure 18. Clinics Case Studies
Figure 19. Others Case Studies
Figure 20. FcRn Inhibitor Report Years Considered
Figure 21. Global FcRn Inhibitor Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 22. Global FcRn Inhibitor Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 23. Global FcRn Inhibitor Market Share by Region: 2024 VS 2031
Figure 24. Global FcRn Inhibitor Market Share by Players in 2024
Figure 25. Global FcRn Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
Figure 26. The Top 10 and 5 Players Market Share by FcRn Inhibitor Revenue in 2024
Figure 27. North America FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. North America FcRn Inhibitor Market Share by Country (2020-2031)
Figure 29. United States FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Canada FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Europe FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Europe FcRn Inhibitor Market Share by Country (2020-2031)
Figure 33. Germany FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. France FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. U.K. FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Italy FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Russia FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Ireland FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Asia-Pacific FcRn Inhibitor Market Share by Region (2020-2031)
Figure 41. China FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Japan FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. South Korea FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Southeast Asia FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. India FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Australia & New Zealand FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Latin America FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Latin America FcRn Inhibitor Market Share by Country (2020-2031)
Figure 49. Mexico FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Brazil FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Middle East & Africa FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Middle East & Africa FcRn Inhibitor Market Share by Country (2020-2031)
Figure 53. Israel FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Saudi Arabia FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. UAE FcRn Inhibitor Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 56. Argenx Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 57. UCB Pharma Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 58. Immunovant Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 59. Johnson & Johnson Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 60. Viridian Therapeutics Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 61. HanAll Biopharma Revenue Growth Rate in FcRn Inhibitor Business (2020-2025)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies